GLP-3 Retatrutide (12mg vials)

Description

Retatrutide is a synthetic triple agonist peptide targeting the GLP-1, GIP and glucagon (GCG) receptors. Peptide Partners supplies Retatrutide in 12mg vials for in-vitro and laboratory research into incretin-receptor signaling, hepatocyte biology and receptor structure.

GLP-3 Retatrutide specifications

Product Format	12mg vials
Vial Size	12mg
Vial Capacity	3 mL
Box Combinations	24mg, 60mg, 120mg, 240mg
Multi-vial Purity	99.64%
Endotoxin Screening	PASSED
Heavy Metals Screening	PENDING
Sterility Screening	PENDING
Independently Tested	YES

Published research on GLP-3 Retatrutide

The summaries below describe peer-reviewed literature for educational and reference purposes only. They do not describe uses of this product, which is sold for laboratory research only.

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

Authors: Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao, H. Eric Xu, Li-Hua Zhao, Dehua Yang & Ming-Wei Wang
Source: https://www.nature.com/articles/s41421-024-00700-0

Cryo-electron microscopy structures of retatrutide bound to the GLP-1, GIP and glucagon receptors show the peptide adopting a single continuous helix. Mutagenesis and cAMP assays identified the conserved and receptor-specific contacts, including GIPR extracellular loop 1, that underlie its triple-receptor agonism.

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids

Authors: Yi Wen, Deven Lemen, Yanzhu Lin, Yan Q Chen, Ajit Regmi, William C Roell, Melissa K Thomas, Mark L Hartman, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Giacomo Ruotolo, Robert J Konrad
Source: https://pubmed.ncbi.nlm.nih.gov/40726454/

This study analyzed circulating ANGPTL3/8 complex and serum lipids using samples from two phase 2 clinical trials, alongside in-vitro experiments in primary human hepatocytes, where retatrutide and glucagon reduced ANGPTL3/8 secretion in a glucagon-receptor-dependent manner.

Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP

Authors: Xin Cui, Yueming Zhu, Lidan Zeng, Mengyuan Zhang, Amad Uddin, Theresa W Gillespie, Lauren E McCullough, Shaying Zhao, Mylin A Torres, Yong Wan
Source: https://pubmed.ncbi.nlm.nih.gov/39868848/

In triple-negative breast cancer cell models co-cultured with cancer-associated adipocytes, researchers examined the hexosamine biosynthetic pathway, YAP O-GlcNAcylation and the EIF3H/YAP proteolytic axis, reporting that retatrutide altered YAP stability through this pathway.

Storage and handling

GLP-3 Retatrutide is supplied for laboratory use. Store unopened vials cold and protected from light, and follow the storage notes on the vial label. Handle only in an appropriate laboratory setting by qualified personnel.

Research use only

This product is sold solely for in-vitro research and laboratory experimentation. It is not a drug, food, supplement or cosmetic, and is not for human or veterinary use. Information on this page is provided for educational purposes only. Purchasers must be qualified research professionals; see our Terms and Conditions.

Browse more Metabolics research peptides, review our testing standards, or see all research peptides.